BLPH — Bellerophon Therapeutics Cashflow Statement
0.000.00%
- $0.23m
- -$4.15m
- 13
- 83
- 29
- 37
Annual cashflow statement for Bellerophon Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 2.81 | -13.3 | -24.7 | -17.8 | -19.8 |
Depreciation | |||||
Non-Cash Items | -21.9 | 0.144 | 2.26 | 0.526 | 0.785 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 3.25 | -0.161 | 2.44 | -5.69 | 1.21 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -15.5 | -12.9 | -19.9 | -22.8 | -17.8 |
Other Investing Cash Flow Items | 3 | 0 | 0 | — | — |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 3 | 0 | 0 | — | — |
Financing Cash Flow Items | -0.028 | -0.069 | -0.186 | — | -0.04 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 0.166 | 6.17 | 57.6 | — | -0.04 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -12.3 | -6.77 | 37.7 | -22.8 | -17.8 |